Comprehensive revenue comparison of pure robotic vs. hybrid robotic surgery for sigmoid colon and rectosigmoid cancer
摘要
Robotic surgery (RS) in colorectal procedures is growing but remains costly. This study evaluated the cost-saving potential of hybrid robotic surgery (hybrid RS), which integrates laparoscopic devices, compared to conventional RS (pure RS).
MethodsThis single-center retrospective study (2022–2024) compared pure RS and hybrid RS for sigmoid and rectosigmoid cancers. Propensity score matching minimizes bias. Total revenue is calculated as the total fee minus the total cost.
ResultsAfter matching, 20 patients (10 per group) were analyzed. Hybrid RS improved total revenue ($3515.15 vs. $3229.33) by reducing the total cost ($3652.45 vs. $4061.33), mainly through lower material costs for staplers and ultrasonic devices. The operative time was shorter, and the safety and pathological outcomes were comparable.
ConclusionsHybrid RS enhances cost efficiency by substituting expensive devices with affordable alternatives, supporting wider adoption of robotic surgery. Further validation using larger studies is necessary.